董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel Spiegelman | 男 | Director | 67 | 未披露 | 未持股 | 2025-12-11 |
| Camilla V. Simpson | 女 | Director | 54 | 1.30万美元 | 未持股 | 2025-12-11 |
| Javier Szwarcberg | -- | Chief Executive Officer and Director | 55 | 未披露 | 未持股 | 2025-12-11 |
| Kirk Ways | 男 | Director | 73 | 未披露 | 未持股 | 2025-12-11 |
| Percival Barretto Ko | 男 | Director | 52 | 未披露 | 未持股 | 2025-12-11 |
| Keli Walbert | -- | Director | -- | 未披露 | 未持股 | 2025-12-11 |
| Michael Grey | 男 | Executive Chairman | 72 | 2.90万美元 | 未持股 | 2025-12-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Samir Gharib | 男 | President and Chief Financial Officer | 43 | 未披露 | 未持股 | 2025-12-11 |
| Javier Szwarcberg | -- | Chief Executive Officer and Director | 55 | 未披露 | 未持股 | 2025-12-11 |
董事简历
中英对照 | 中文 | 英文- Daniel Spiegelman
-
Daniel Spiegelman已同意在本次发行完成后担任我们的董事会成员。Spiegelman先生目前为各种生命科学公司提供咨询和董事会服务，包括担任董事长的Tizona Therapeutics公司和担任董事会成员和审计委员会主席的Myriad Genetics公司、Spruce Biosciences公司和Opthea Limited公司。2012年5月至2020年1月，Spiegelman先生担任BioMarin Pharmaceutical首席财务官的执行Vice President，该公司的年收入增长到20亿美元，市值达到150亿美元。Spiegelman从1998年1月到2009年5月担任CV Therapeutics，Inc.（一家生物制药公司，在出售给Gilead Sciences之前开发和销售新型心血管药物）首席财务官。从1991年7月到1998年1月，Spiegelman先生在Genentech，Inc.担任过各种职务，现在是罗氏集团的成员，最近担任财务主管。Spiegelman自2008年10月起担任多家其他生物制药公司的董事，包括CascadianTherapeutics，Inc.（原Oncothyreon，Inc.），该公司于2018年3月与SeattleGenetics，Inc.合并，Relypsa，Inc.自2014年6月起担任董事，直至2016年9月与Galenica AG合并，Anthera Pharmaceuticals，2010年2月至2014年6月，Affymax，Inc.，2006年10月至2013年6月，Omeros Corporation，2009年12月至2012年6月，CyclacelPharmaceuticals，Inc.，2004年9月至2012年6月。Spiegelman先生在斯坦福大学（Stanford University）获得文学学士学位，并在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位。
Daniel Spiegelman,has served as a member of the Board since September 2020. Mr. Spiegelman currently provides consulting services to various life sciences companies and has served as a Venture Partner at Samsara BioCapital since 2023. From May 2012 to January 2020, Mr. Spiegelman was the Executive Vice President and Chief Financial Officer of BioMarin Pharmaceutical Inc. ("BioMarin"), a biotechnology company. Prior to BioMarin, Mr. Spiegelman served as a consultant to provide strategic financial management support a portfolio of public and private life science companies. From January 1998 to May 2009, Mr. Spiegelman was the Chief Financial Officer of CV Therapeutics, Inc., a biopharmaceutical company. From July 1991 to January 1998, Mr. Spiegelman served in various roles at Genentech, Inc., (now a member of the Roche Group) most recently as Treasurer. Mr. Spiegelman has served as a director of Maze Therapeutics, Inc., a public biologics drug developer, since October 2020, of vTv Therapeutics, Inc., a public biopharmaceutical company, since June 2024 and of Kyverna Therapeutics, Inc., a public pharmaceutical company, since April 2021. Mr. Spiegelman served as a director of Myriad Genetics, Inc. a public molecular diagnostic company, from May 2020 to June 2024 and as a director of Opthea Limited, a public biologics drug developer, from October 2020 to April 2024. Mr. Spiegelman has served as director and chair of Tizona Therapeutics, Inc., a private biopharmaceutical company, since May 2019 and as director of BlueJay Therapeutics, Inc., a private biopharmaceutical company, since October 2024. Mr. Spiegelman received a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business. - Daniel Spiegelman已同意在本次发行完成后担任我们的董事会成员。Spiegelman先生目前为各种生命科学公司提供咨询和董事会服务，包括担任董事长的Tizona Therapeutics公司和担任董事会成员和审计委员会主席的Myriad Genetics公司、Spruce Biosciences公司和Opthea Limited公司。2012年5月至2020年1月，Spiegelman先生担任BioMarin Pharmaceutical首席财务官的执行Vice President，该公司的年收入增长到20亿美元，市值达到150亿美元。Spiegelman从1998年1月到2009年5月担任CV Therapeutics，Inc.（一家生物制药公司，在出售给Gilead Sciences之前开发和销售新型心血管药物）首席财务官。从1991年7月到1998年1月，Spiegelman先生在Genentech，Inc.担任过各种职务，现在是罗氏集团的成员，最近担任财务主管。Spiegelman自2008年10月起担任多家其他生物制药公司的董事，包括CascadianTherapeutics，Inc.（原Oncothyreon，Inc.），该公司于2018年3月与SeattleGenetics，Inc.合并，Relypsa，Inc.自2014年6月起担任董事，直至2016年9月与Galenica AG合并，Anthera Pharmaceuticals，2010年2月至2014年6月，Affymax，Inc.，2006年10月至2013年6月，Omeros Corporation，2009年12月至2012年6月，CyclacelPharmaceuticals，Inc.，2004年9月至2012年6月。Spiegelman先生在斯坦福大学（Stanford University）获得文学学士学位，并在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位。
- Daniel Spiegelman,has served as a member of the Board since September 2020. Mr. Spiegelman currently provides consulting services to various life sciences companies and has served as a Venture Partner at Samsara BioCapital since 2023. From May 2012 to January 2020, Mr. Spiegelman was the Executive Vice President and Chief Financial Officer of BioMarin Pharmaceutical Inc. ("BioMarin"), a biotechnology company. Prior to BioMarin, Mr. Spiegelman served as a consultant to provide strategic financial management support a portfolio of public and private life science companies. From January 1998 to May 2009, Mr. Spiegelman was the Chief Financial Officer of CV Therapeutics, Inc., a biopharmaceutical company. From July 1991 to January 1998, Mr. Spiegelman served in various roles at Genentech, Inc., (now a member of the Roche Group) most recently as Treasurer. Mr. Spiegelman has served as a director of Maze Therapeutics, Inc., a public biologics drug developer, since October 2020, of vTv Therapeutics, Inc., a public biopharmaceutical company, since June 2024 and of Kyverna Therapeutics, Inc., a public pharmaceutical company, since April 2021. Mr. Spiegelman served as a director of Myriad Genetics, Inc. a public molecular diagnostic company, from May 2020 to June 2024 and as a director of Opthea Limited, a public biologics drug developer, from October 2020 to April 2024. Mr. Spiegelman has served as director and chair of Tizona Therapeutics, Inc., a private biopharmaceutical company, since May 2019 and as director of BlueJay Therapeutics, Inc., a private biopharmaceutical company, since October 2024. Mr. Spiegelman received a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.
- Camilla V. Simpson
-
Camilla V. Simpson，自2023年4月起担任Gri Bio，Inc.董事会成员。她自2017年10月起担任Spruce Biosciences董事会成员。自2021年4月以来，辛普森女士一直担任Zehna Therapeutics的首席执行官，这是一家处于早期阶段的生物技术公司，是克利夫兰诊所的衍生公司。自2019年4月以来，辛普森女士一直担任Rare Strategic，LLC的管理成员和总裁，为生物技术公司提供战略咨询和咨询服务。Simpson女士于2020年12月加入Dyve Biosciences董事会。从2017年4月到2019年4月，辛普森女士在BioMarin担任高级副总裁兼产品组合开发主管，负责公司和研发治理、项目领导、项目管理、竞争情报、组合战略和业务分析。2014年10月至2017年4月，辛普森女士担任BioMarin全球监管事务集团副总裁，2014年3月至2014年10月，辛普森女士担任BioMarin欧盟监管事务副总裁。她还在Shire工作了12年，在担任多个职务后，她的职责不断增加，最终担任监管事务早期发展和业务发展副总裁。辛普森女士拥有爱尔兰戈尔韦大学学院的理学学士学位和理学学士学位。英国金斯顿大学荣誉学位，英国伦敦大学理学硕士学位。
Camilla V. Simpson has served as a member of Spruce Biosciences, Inc.'s board of directors, a publicly traded company (NASDAQ: SPRB), since October 2017. Since April 2021, Ms. Simpson has been Chief Executive Officer of Zehna Therapeutics, an early stage biotechnology company and a spin out from the Cleveland Clinic. Since April 2019, Ms. Simpson has been the Managing Member and President of Rare Strategic, LLC where she provides strategic advice and consulting services to biotechnology companies. Ms. Simpson joined the board of directors of Dyve Biosciences in December 2020. From April 2017 to April 2019, Ms. Simpson was SVP, Head of Product Portfolio Development at BioMarin where she was responsible for corporate and Research and Development governance, program leadership, project management, competitive intelligence, portfolio strategy, and biness analytics. From October 2014 to April 2017, Ms. Simpson was Group Vice President Global Regulatory Affairs at BioMarin, and from March 2014 to October 2014, Ms. Simpson was Vice President Regulatory Affairs EU at BioMarin. She also spent 12 years at Shire, where after multiple roles of increasing responsibility, ultimately held the position of Vice President of Regulatory Affairs Early Development and Biness Development. Ms. Simpson holds a Bachelor of Science from University College Galway, Ireland, a Bachelors of Science (Honors) from Kingston University, United Kingdom, and an Master of Science with distinction from University of London, UK. - Camilla V. Simpson，自2023年4月起担任Gri Bio，Inc.董事会成员。她自2017年10月起担任Spruce Biosciences董事会成员。自2021年4月以来，辛普森女士一直担任Zehna Therapeutics的首席执行官，这是一家处于早期阶段的生物技术公司，是克利夫兰诊所的衍生公司。自2019年4月以来，辛普森女士一直担任Rare Strategic，LLC的管理成员和总裁，为生物技术公司提供战略咨询和咨询服务。Simpson女士于2020年12月加入Dyve Biosciences董事会。从2017年4月到2019年4月，辛普森女士在BioMarin担任高级副总裁兼产品组合开发主管，负责公司和研发治理、项目领导、项目管理、竞争情报、组合战略和业务分析。2014年10月至2017年4月，辛普森女士担任BioMarin全球监管事务集团副总裁，2014年3月至2014年10月，辛普森女士担任BioMarin欧盟监管事务副总裁。她还在Shire工作了12年，在担任多个职务后，她的职责不断增加，最终担任监管事务早期发展和业务发展副总裁。辛普森女士拥有爱尔兰戈尔韦大学学院的理学学士学位和理学学士学位。英国金斯顿大学荣誉学位，英国伦敦大学理学硕士学位。
- Camilla V. Simpson has served as a member of Spruce Biosciences, Inc.'s board of directors, a publicly traded company (NASDAQ: SPRB), since October 2017. Since April 2021, Ms. Simpson has been Chief Executive Officer of Zehna Therapeutics, an early stage biotechnology company and a spin out from the Cleveland Clinic. Since April 2019, Ms. Simpson has been the Managing Member and President of Rare Strategic, LLC where she provides strategic advice and consulting services to biotechnology companies. Ms. Simpson joined the board of directors of Dyve Biosciences in December 2020. From April 2017 to April 2019, Ms. Simpson was SVP, Head of Product Portfolio Development at BioMarin where she was responsible for corporate and Research and Development governance, program leadership, project management, competitive intelligence, portfolio strategy, and biness analytics. From October 2014 to April 2017, Ms. Simpson was Group Vice President Global Regulatory Affairs at BioMarin, and from March 2014 to October 2014, Ms. Simpson was Vice President Regulatory Affairs EU at BioMarin. She also spent 12 years at Shire, where after multiple roles of increasing responsibility, ultimately held the position of Vice President of Regulatory Affairs Early Development and Biness Development. Ms. Simpson holds a Bachelor of Science from University College Galway, Ireland, a Bachelors of Science (Honors) from Kingston University, United Kingdom, and an Master of Science with distinction from University of London, UK.
- Javier Szwarcberg
-
Javier Szwarcberg，自2022年1月起担任首席执行官和董事会成员。Szwarcberg博士此前曾于2020年2月至2022年1月担任BioMarin的集团副总裁、产品和产品组合开发主管。在加入BioMarin之前，Szwarcberg博士于2017年10月至2020年2月期间担任生物技术公司Ultragenyx Pharmaceutical Inc.的项目和投资组合管理高级副总裁。2016年10月至2017年10月，Szwarcberg博士担任上市生物制药公司Horizon Pharma PLC（“Horizon”）的临床开发和业务发展副总裁。Szwarcberg博士获得了布宜诺斯艾利斯大学的医学博士学位和哈佛大学T.H. Chan公共卫生学院的公共卫生硕士学位。董事会和提名委员会认为，Szwarcberg博士在生物技术和制药行业的丰富经验使他有资格担任董事会成员。
Javier Szwarcberg,has served as Chief Executive Officer and a member of the Board since January 2022. Dr. Szwarcberg previously served as Group Vice President, Head of Product and Portfolio Development for BioMarin from February 2020 to January 2022. Prior to joining BioMarin, Dr. Szwarcberg served as Senior Vice President, Program and Portfolio Management for Ultragenyx Pharmaceutical Inc., a biotechnology company, from October 2017 to February 2020. From October 2016 to October 2017, Dr. Szwarcberg served as Vice President of Clinical Development and Business Development for Horizon Pharma plc ("Horizon"), a public biopharmaceutical company. Dr. Szwarcberg received an M.D. from the University of Buenos Aires and an MPH from the Harvard T.H. Chan School of Public Health. - Javier Szwarcberg，自2022年1月起担任首席执行官和董事会成员。Szwarcberg博士此前曾于2020年2月至2022年1月担任BioMarin的集团副总裁、产品和产品组合开发主管。在加入BioMarin之前，Szwarcberg博士于2017年10月至2020年2月期间担任生物技术公司Ultragenyx Pharmaceutical Inc.的项目和投资组合管理高级副总裁。2016年10月至2017年10月，Szwarcberg博士担任上市生物制药公司Horizon Pharma PLC（“Horizon”）的临床开发和业务发展副总裁。Szwarcberg博士获得了布宜诺斯艾利斯大学的医学博士学位和哈佛大学T.H. Chan公共卫生学院的公共卫生硕士学位。董事会和提名委员会认为，Szwarcberg博士在生物技术和制药行业的丰富经验使他有资格担任董事会成员。
- Javier Szwarcberg,has served as Chief Executive Officer and a member of the Board since January 2022. Dr. Szwarcberg previously served as Group Vice President, Head of Product and Portfolio Development for BioMarin from February 2020 to January 2022. Prior to joining BioMarin, Dr. Szwarcberg served as Senior Vice President, Program and Portfolio Management for Ultragenyx Pharmaceutical Inc., a biotechnology company, from October 2017 to February 2020. From October 2016 to October 2017, Dr. Szwarcberg served as Vice President of Clinical Development and Business Development for Horizon Pharma plc ("Horizon"), a public biopharmaceutical company. Dr. Szwarcberg received an M.D. from the University of Buenos Aires and an MPH from the Harvard T.H. Chan School of Public Health.
- Kirk Ways
-
Kirk Ways，自2021年6月起担任董事会成员，自2024年12月起担任临时首席医疗官。Ways博士于2023年11月至2024年7月期间担任MBX的临时首席医疗官。2018年10月至2021年1月，Ways博士担任生物制药公司Nuvelution Pharma，Inc.（“Nuvelution”）的首席医疗官。在加入Nuvelution之前，Ways博士曾在生物制药公司Janssen Pharmaceuticals，Inc.（简称“Janssen”）担任心血管和代谢领域的开发主管。在加入杨森之前，Ways博士曾在多家生命科学公司担任领导职务，包括BioStratum Incorporated担任副总裁兼首席开发官，Aventis，Inc.担任高级全球医疗负责人和项目团队负责人，Lilly Research Laboratories担任研究员，负责治疗糖尿病慢性并发症的药物的临床前和临床开发。在加入制药行业之前，Ways博士曾担任东卡罗莱纳医学院糖尿病中心主任、内科副主席、内分泌科科长和医学教授。Ways博士在糖尿病和癌症领域撰写了一百多篇出版物。Ways博士以优异的成绩获得了北卡罗来纳大学的医学博士学位和药理学博士学位，并以优异的成绩以学士学位毕业于桥水学院。
Kirk Ways,has served on the Board since June 2021 and as interim Chief Medical officer since December 2024. Dr. Ways has served as interim Chief Medical Officer of MBX from November 2023 to July 2024. From October 2018 to January 2021, Dr. Ways served as Chief Medical Officer of Nuvelution Pharma, Inc. ("Nuvelution"), a biopharmaceutical company. Prior to joining Nuvelution, Dr. Ways served as Development Head of Cardiovascular and Metabolism at Janssen Pharmaceuticals, Inc. ("Janssen"), a biopharmaceutical company. Prior to joining Janssen, Dr. Ways served in leadership capacities at several life sciences companies, including BioStratum Incorporated as Vice President and Chief Development Officer, Aventis, Inc. as Senior Global Medical Leader and Project Team Leader and Lilly Research Laboratories as a Research Fellow with responsibilities for the preclinical and clinical development for agents treating the chronic complications of diabetes. Prior to joining the pharmaceutical industry, Dr. Ways served as Director of the Diabetes Center, Vice Chairman for the Department of Internal Medicine, Endocrinology Section Head and Professor of Medicine at East Carolina School of Medicine. Dr. Ways has authored more than one hundred publications in the fields of diabetes and cancer. Dr. Ways earned his M.D. with honors and a Ph.D. in Pharmacology from the University of North Carolina and graduated with a B.A. magna cum laude from Bridgewater College. - Kirk Ways，自2021年6月起担任董事会成员，自2024年12月起担任临时首席医疗官。Ways博士于2023年11月至2024年7月期间担任MBX的临时首席医疗官。2018年10月至2021年1月，Ways博士担任生物制药公司Nuvelution Pharma，Inc.（“Nuvelution”）的首席医疗官。在加入Nuvelution之前，Ways博士曾在生物制药公司Janssen Pharmaceuticals，Inc.（简称“Janssen”）担任心血管和代谢领域的开发主管。在加入杨森之前，Ways博士曾在多家生命科学公司担任领导职务，包括BioStratum Incorporated担任副总裁兼首席开发官，Aventis，Inc.担任高级全球医疗负责人和项目团队负责人，Lilly Research Laboratories担任研究员，负责治疗糖尿病慢性并发症的药物的临床前和临床开发。在加入制药行业之前，Ways博士曾担任东卡罗莱纳医学院糖尿病中心主任、内科副主席、内分泌科科长和医学教授。Ways博士在糖尿病和癌症领域撰写了一百多篇出版物。Ways博士以优异的成绩获得了北卡罗来纳大学的医学博士学位和药理学博士学位，并以优异的成绩以学士学位毕业于桥水学院。
- Kirk Ways,has served on the Board since June 2021 and as interim Chief Medical officer since December 2024. Dr. Ways has served as interim Chief Medical Officer of MBX from November 2023 to July 2024. From October 2018 to January 2021, Dr. Ways served as Chief Medical Officer of Nuvelution Pharma, Inc. ("Nuvelution"), a biopharmaceutical company. Prior to joining Nuvelution, Dr. Ways served as Development Head of Cardiovascular and Metabolism at Janssen Pharmaceuticals, Inc. ("Janssen"), a biopharmaceutical company. Prior to joining Janssen, Dr. Ways served in leadership capacities at several life sciences companies, including BioStratum Incorporated as Vice President and Chief Development Officer, Aventis, Inc. as Senior Global Medical Leader and Project Team Leader and Lilly Research Laboratories as a Research Fellow with responsibilities for the preclinical and clinical development for agents treating the chronic complications of diabetes. Prior to joining the pharmaceutical industry, Dr. Ways served as Director of the Diabetes Center, Vice Chairman for the Department of Internal Medicine, Endocrinology Section Head and Professor of Medicine at East Carolina School of Medicine. Dr. Ways has authored more than one hundred publications in the fields of diabetes and cancer. Dr. Ways earned his M.D. with honors and a Ph.D. in Pharmacology from the University of North Carolina and graduated with a B.A. magna cum laude from Bridgewater College.
- Percival Barretto Ko
-
Percival Barretto Ko，自2023年5月起担任董事会成员。最近，Barretto-Ko先生担任制药公司Plexium，Inc.（“Plexium”）的总裁兼首席执行官。在加入Plexium之前，Barretto-Ko先生曾于2005年至2021年在制药公司Astellas Pharma Inc.担任过多个职务，包括首席商务官和美国总裁。在加入安斯泰来之前，巴雷托-科曾于2001年至2005年在制药公司罗氏英国和美国担任越来越高级的职务。Barretto-Ko先生自2022年1月起担任私营制药公司Alessa Therapeutics，Inc.的董事会成员。Barretto-Ko先生以优异的成绩获得了康奈尔大学生物科学学士学位和耶鲁大学工商管理硕士学位。此外，Barretto-Ko先生还曾在麻省理工学院斯隆管理学院担任斯隆创新和全球领导力研究员，在那里他获得了管理学硕士学位。
Percival Barretto Ko,has served as a member of the Board since May 2023. Most recently, Mr. Barretto-Ko served as President and Chief Executive Officer at Plexium, Inc., a pharmaceutical company ("Plexium"). Prior to joining Plexium, Mr. Barretto-Ko served in numerous roles, including Chief Business Officer and President U.S., at Astellas Pharma Inc., a pharmaceutical company, from 2005 to 2021. Prior to joining Astellas, Mr. Barretto-Ko served in increasingly senior roles at Roche UK and US, a pharmaceutical company, from 2001 to 2005. Mr. Barretto-Ko has served on the board of directors for Alessa Therapeutics, Inc., a private pharmaceutical company, since January 2022. Mr. Barretto-Ko earned a B.S. in Biological Sciences with Honors from Cornell University and an M.B.A. from Yale University. In addition, Mr. Barretto-Ko served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded an M.Sc. in Management. - Percival Barretto Ko，自2023年5月起担任董事会成员。最近，Barretto-Ko先生担任制药公司Plexium，Inc.（“Plexium”）的总裁兼首席执行官。在加入Plexium之前，Barretto-Ko先生曾于2005年至2021年在制药公司Astellas Pharma Inc.担任过多个职务，包括首席商务官和美国总裁。在加入安斯泰来之前，巴雷托-科曾于2001年至2005年在制药公司罗氏英国和美国担任越来越高级的职务。Barretto-Ko先生自2022年1月起担任私营制药公司Alessa Therapeutics，Inc.的董事会成员。Barretto-Ko先生以优异的成绩获得了康奈尔大学生物科学学士学位和耶鲁大学工商管理硕士学位。此外，Barretto-Ko先生还曾在麻省理工学院斯隆管理学院担任斯隆创新和全球领导力研究员，在那里他获得了管理学硕士学位。
- Percival Barretto Ko,has served as a member of the Board since May 2023. Most recently, Mr. Barretto-Ko served as President and Chief Executive Officer at Plexium, Inc., a pharmaceutical company ("Plexium"). Prior to joining Plexium, Mr. Barretto-Ko served in numerous roles, including Chief Business Officer and President U.S., at Astellas Pharma Inc., a pharmaceutical company, from 2005 to 2021. Prior to joining Astellas, Mr. Barretto-Ko served in increasingly senior roles at Roche UK and US, a pharmaceutical company, from 2001 to 2005. Mr. Barretto-Ko has served on the board of directors for Alessa Therapeutics, Inc., a private pharmaceutical company, since January 2022. Mr. Barretto-Ko earned a B.S. in Biological Sciences with Honors from Cornell University and an M.B.A. from Yale University. In addition, Mr. Barretto-Ko served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded an M.Sc. in Management.
- Keli Walbert
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Michael Grey
-
Michael Grey，自2017年4月起担任董事会执行主席，并于2021年11月至2022年1月担任Spruce Biosciences, Inc.临时首席执行官。此外，Grey先生自2020年1月起担任上市生物制药公司Mirum Pharmaceuticals, Inc.的董事长，并自2018年5月起担任Mirum的董事。Grey先生此前曾于2019年3月至2019年12月担任Mirum执行主席，并于2018年5月至2019年3月担任Mirum首席执行官。Grey先生于2017年12月至2024年10月担任Reneo Pharmaceuticals，Inc.（于2024年与生物制药公司OnKure，Inc.合并）的执行主席，并自2024年10月起担任OnKure的董事。Grey先生自2020年9月起担任Plexium执行董事长。他自2021年5月起担任私营制药公司Sorriso Pharmaceuticals，Inc.的董事长，并自2023年11月起担任私营生物技术公司Theolytics Ltd.的执行主席。Grey先生此前曾于2005年12月至2021年5月担任BioMarin的董事，并于2014年11月至2021年6月担任生物制药公司Mirati Therapeutics, Inc.的董事。他还自2010年1月起担任风险投资公司Pappas Ventures的风险合伙人，于2019年1月至2020年4月担任私营生物制药公司Curzion Pharmaceuticals，Inc.的董事，该公司于2020年4月被Horizon收购，并于2011年9月至2023年10月担任Horizon的董事。Grey先生于2019年1月至2019年9月担任Curzion总裁兼首席执行官，于2015年10月至2017年1月担任Amplyx Pharmaceuticals，Inc.总裁兼首席执行官，并于2014年9月至2017年12月担任Reneo董事长兼首席执行官。2011年2月至2014年6月，Grey先生担任Lumena Pharmaceuticals, Inc.的总裁兼首席执行官，该公司于2014年6月被Shire plc收购。Grey先生在制药和生物技术行业拥有超过45年的经验，曾在多家公司担任高级职务，包括SGX Pharmaceuticals，Inc.（于2008年出售给Eli Lilly and Company）的总裁兼首席执行官、Trega Biosciences，Inc.（于2001年出售给LION Bioscience，Inc.）的总裁兼首席执行官以及BioChem Therapeutic Inc.的总裁。在此之前，Grey先生曾在Glaxo，Inc.和Glaxo Holdings PLC担任多个职务，最终担任公司发展副总裁和国际许可总监。Grey先生在英国Nottingham大学获得化学学士学位。
Michael Grey,has served as Executive Chairman of the Board since April 2017 and served as Spruce Biosciences, Inc. Interim Chief Executive Officer from November 2021 to January 2022. In addition, Mr. Grey has served as Chairman of Mirum Pharmaceuticals, Inc., a public biopharmaceutical company, since January 2020, and has been a director of Mirum since May 2018. Mr. Grey previously served as Executive Chairman of Mirum from March 2019 to December 2019 and Chief Executive Officer of Mirum from May 2018 to March 2019. Mr. Grey served as Executive Chairman of Reneo Pharmaceuticals, Inc. from December 2017 to October 2024 (merged with OnKure, Inc., a biopharmaceutical company, in 2024) and has served as a director for OnKure since October 2024. Mr. Grey has served as Executive Chairman of Plexium since September 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc., a private pharmaceutical company since May 2021 and as Executive Chair of Theolytics Ltd., a private biotechnology company, since November 2023. Mr. Grey previously served as a director of BioMarin from December 2005 to May 2021 and as director of Mirati Therapeutics, Inc., a biopharmaceutical company, from November 2014 to June 2021. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010, as a director of Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, which was acquired in April 2020 by Horizon, from January 2019 to April 2020, and as a director at Horizon from September 2011 to October 2023. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom. - Michael Grey，自2017年4月起担任董事会执行主席，并于2021年11月至2022年1月担任Spruce Biosciences, Inc.临时首席执行官。此外，Grey先生自2020年1月起担任上市生物制药公司Mirum Pharmaceuticals, Inc.的董事长，并自2018年5月起担任Mirum的董事。Grey先生此前曾于2019年3月至2019年12月担任Mirum执行主席，并于2018年5月至2019年3月担任Mirum首席执行官。Grey先生于2017年12月至2024年10月担任Reneo Pharmaceuticals，Inc.（于2024年与生物制药公司OnKure，Inc.合并）的执行主席，并自2024年10月起担任OnKure的董事。Grey先生自2020年9月起担任Plexium执行董事长。他自2021年5月起担任私营制药公司Sorriso Pharmaceuticals，Inc.的董事长，并自2023年11月起担任私营生物技术公司Theolytics Ltd.的执行主席。Grey先生此前曾于2005年12月至2021年5月担任BioMarin的董事，并于2014年11月至2021年6月担任生物制药公司Mirati Therapeutics, Inc.的董事。他还自2010年1月起担任风险投资公司Pappas Ventures的风险合伙人，于2019年1月至2020年4月担任私营生物制药公司Curzion Pharmaceuticals，Inc.的董事，该公司于2020年4月被Horizon收购，并于2011年9月至2023年10月担任Horizon的董事。Grey先生于2019年1月至2019年9月担任Curzion总裁兼首席执行官，于2015年10月至2017年1月担任Amplyx Pharmaceuticals，Inc.总裁兼首席执行官，并于2014年9月至2017年12月担任Reneo董事长兼首席执行官。2011年2月至2014年6月，Grey先生担任Lumena Pharmaceuticals, Inc.的总裁兼首席执行官，该公司于2014年6月被Shire plc收购。Grey先生在制药和生物技术行业拥有超过45年的经验，曾在多家公司担任高级职务，包括SGX Pharmaceuticals，Inc.（于2008年出售给Eli Lilly and Company）的总裁兼首席执行官、Trega Biosciences，Inc.（于2001年出售给LION Bioscience，Inc.）的总裁兼首席执行官以及BioChem Therapeutic Inc.的总裁。在此之前，Grey先生曾在Glaxo，Inc.和Glaxo Holdings PLC担任多个职务，最终担任公司发展副总裁和国际许可总监。Grey先生在英国Nottingham大学获得化学学士学位。
- Michael Grey,has served as Executive Chairman of the Board since April 2017 and served as Spruce Biosciences, Inc. Interim Chief Executive Officer from November 2021 to January 2022. In addition, Mr. Grey has served as Chairman of Mirum Pharmaceuticals, Inc., a public biopharmaceutical company, since January 2020, and has been a director of Mirum since May 2018. Mr. Grey previously served as Executive Chairman of Mirum from March 2019 to December 2019 and Chief Executive Officer of Mirum from May 2018 to March 2019. Mr. Grey served as Executive Chairman of Reneo Pharmaceuticals, Inc. from December 2017 to October 2024 (merged with OnKure, Inc., a biopharmaceutical company, in 2024) and has served as a director for OnKure since October 2024. Mr. Grey has served as Executive Chairman of Plexium since September 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc., a private pharmaceutical company since May 2021 and as Executive Chair of Theolytics Ltd., a private biotechnology company, since November 2023. Mr. Grey previously served as a director of BioMarin from December 2005 to May 2021 and as director of Mirati Therapeutics, Inc., a biopharmaceutical company, from November 2014 to June 2021. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010, as a director of Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, which was acquired in April 2020 by Horizon, from January 2019 to April 2020, and as a director at Horizon from September 2011 to October 2023. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom.
高管简历
中英对照 | 中文 | 英文- Samir Gharib
Samir Gharib自2020年5月以来一直是我们的首席财务官。从2019年9月至2020年5月，Gharib先生向具有Benchmark Financial Partners或Benchmark（一家战略财务咨询公司）的各种公司提供咨询服务。从2018年10月到2019年9月，Gharib先生担任Stemedica Cell Technologies，Inc.的首席财务官，该公司是一家全球制药公司，专注于为服务不足的医疗状况开发细胞疗法并将其商业化。从2017年9月至2018年10月，Gharib先生担任Benchmark的董事总经理。2013年10月至2017年9月，Gharib先生在RevanceTherapeutics，Inc.（一家商业阶段的生物技术公司）担任越来越重要的职务，包括财务和行政Vice President。2011年1月至2013年9月，Gharib先生是Talon Therapeutics，Inc.的公司财务总监兼财务总监。Garib先生自2017年11月起担任Cancer CarePoint的董事，自2020年1月起担任Berkeley Skydeck的顾问。Gharib先生在加州大学伯克利分校哈斯商学院（Haas School of Business at the University of California at Berkeley）获得理学学士学位和工商管理硕士学位，是一名在加利福尼亚州获得执照的活跃注册会计师。
Samir Gharib,has served as President since January 2022 and as Chief Financial Officer since May 2020. From September 2019 to May 2020, Mr. Gharib provided consulting services to various companies with Benchmark Financial Partners ("Benchmark"), a strategic financial advisory firm. From October 2018 to September 2019, Mr. Gharib was the Chief Financial Officer of Stemedica Cell Technologies, Inc., a global pharmaceutical company focused on the development and commercialization of cell therapeutics for underserved medical conditions. From September 2017 to October 2018, Mr. Gharib served as Managing Director of Benchmark. From October 2013 to September 2017, Mr. Gharib held positions of increasing responsibility at Revance Therapeutics, Inc., a commercial-stage biotechnology company, including Vice President of Finance and Administration. From January 2011 to September 2013, Mr. Gharib was the Corporate Controller, Director of Finance for Talon Therapeutics, Inc. Mr. Gharib has been an advisor to Berkeley SkyDeck since January 2020. Mr. Gharib received a Bachelor of Science and M.B.A. from the Haas School of Business at the University of California at Berkeley, and is an active Certified Public Accountant licensed in the State of California.- Samir Gharib自2020年5月以来一直是我们的首席财务官。从2019年9月至2020年5月，Gharib先生向具有Benchmark Financial Partners或Benchmark（一家战略财务咨询公司）的各种公司提供咨询服务。从2018年10月到2019年9月，Gharib先生担任Stemedica Cell Technologies，Inc.的首席财务官，该公司是一家全球制药公司，专注于为服务不足的医疗状况开发细胞疗法并将其商业化。从2017年9月至2018年10月，Gharib先生担任Benchmark的董事总经理。2013年10月至2017年9月，Gharib先生在RevanceTherapeutics，Inc.（一家商业阶段的生物技术公司）担任越来越重要的职务，包括财务和行政Vice President。2011年1月至2013年9月，Gharib先生是Talon Therapeutics，Inc.的公司财务总监兼财务总监。Garib先生自2017年11月起担任Cancer CarePoint的董事，自2020年1月起担任Berkeley Skydeck的顾问。Gharib先生在加州大学伯克利分校哈斯商学院（Haas School of Business at the University of California at Berkeley）获得理学学士学位和工商管理硕士学位，是一名在加利福尼亚州获得执照的活跃注册会计师。
- Samir Gharib,has served as President since January 2022 and as Chief Financial Officer since May 2020. From September 2019 to May 2020, Mr. Gharib provided consulting services to various companies with Benchmark Financial Partners ("Benchmark"), a strategic financial advisory firm. From October 2018 to September 2019, Mr. Gharib was the Chief Financial Officer of Stemedica Cell Technologies, Inc., a global pharmaceutical company focused on the development and commercialization of cell therapeutics for underserved medical conditions. From September 2017 to October 2018, Mr. Gharib served as Managing Director of Benchmark. From October 2013 to September 2017, Mr. Gharib held positions of increasing responsibility at Revance Therapeutics, Inc., a commercial-stage biotechnology company, including Vice President of Finance and Administration. From January 2011 to September 2013, Mr. Gharib was the Corporate Controller, Director of Finance for Talon Therapeutics, Inc. Mr. Gharib has been an advisor to Berkeley SkyDeck since January 2020. Mr. Gharib received a Bachelor of Science and M.B.A. from the Haas School of Business at the University of California at Berkeley, and is an active Certified Public Accountant licensed in the State of California.
- Javier Szwarcberg
Javier Szwarcberg，自2022年1月起担任首席执行官和董事会成员。Szwarcberg博士此前曾于2020年2月至2022年1月担任BioMarin的集团副总裁、产品和产品组合开发主管。在加入BioMarin之前，Szwarcberg博士于2017年10月至2020年2月期间担任生物技术公司Ultragenyx Pharmaceutical Inc.的项目和投资组合管理高级副总裁。2016年10月至2017年10月，Szwarcberg博士担任上市生物制药公司Horizon Pharma PLC（“Horizon”）的临床开发和业务发展副总裁。Szwarcberg博士获得了布宜诺斯艾利斯大学的医学博士学位和哈佛大学T.H. Chan公共卫生学院的公共卫生硕士学位。董事会和提名委员会认为，Szwarcberg博士在生物技术和制药行业的丰富经验使他有资格担任董事会成员。
Javier Szwarcberg,has served as Chief Executive Officer and a member of the Board since January 2022. Dr. Szwarcberg previously served as Group Vice President, Head of Product and Portfolio Development for BioMarin from February 2020 to January 2022. Prior to joining BioMarin, Dr. Szwarcberg served as Senior Vice President, Program and Portfolio Management for Ultragenyx Pharmaceutical Inc., a biotechnology company, from October 2017 to February 2020. From October 2016 to October 2017, Dr. Szwarcberg served as Vice President of Clinical Development and Business Development for Horizon Pharma plc ("Horizon"), a public biopharmaceutical company. Dr. Szwarcberg received an M.D. from the University of Buenos Aires and an MPH from the Harvard T.H. Chan School of Public Health.- Javier Szwarcberg，自2022年1月起担任首席执行官和董事会成员。Szwarcberg博士此前曾于2020年2月至2022年1月担任BioMarin的集团副总裁、产品和产品组合开发主管。在加入BioMarin之前，Szwarcberg博士于2017年10月至2020年2月期间担任生物技术公司Ultragenyx Pharmaceutical Inc.的项目和投资组合管理高级副总裁。2016年10月至2017年10月，Szwarcberg博士担任上市生物制药公司Horizon Pharma PLC（“Horizon”）的临床开发和业务发展副总裁。Szwarcberg博士获得了布宜诺斯艾利斯大学的医学博士学位和哈佛大学T.H. Chan公共卫生学院的公共卫生硕士学位。董事会和提名委员会认为，Szwarcberg博士在生物技术和制药行业的丰富经验使他有资格担任董事会成员。
- Javier Szwarcberg,has served as Chief Executive Officer and a member of the Board since January 2022. Dr. Szwarcberg previously served as Group Vice President, Head of Product and Portfolio Development for BioMarin from February 2020 to January 2022. Prior to joining BioMarin, Dr. Szwarcberg served as Senior Vice President, Program and Portfolio Management for Ultragenyx Pharmaceutical Inc., a biotechnology company, from October 2017 to February 2020. From October 2016 to October 2017, Dr. Szwarcberg served as Vice President of Clinical Development and Business Development for Horizon Pharma plc ("Horizon"), a public biopharmaceutical company. Dr. Szwarcberg received an M.D. from the University of Buenos Aires and an MPH from the Harvard T.H. Chan School of Public Health.